Cabaletta Bio | Investor Presentation Deck | 23 slides

Cabaletta Bio · 2022-10
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON

Slide inventory

23
every slide · same image gating as the playbook
01
Slide 1
Includes Exhibit 99.1 reference, typical for SEC-filed investor decks.front_matter
03
inspire_vision
Open slide detailLoop · Golden Circle
04
The slide uses a bulleted list structure to summarize key clinical milestones and financial position.summarize
Open slide detailLoop · Golden Circle
05
The slide uses a comparative structure to explain two different CAR-T approaches.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
06
Central illustration is a stylized human body with vasculature; six category labels positioned around the figure with bulleted disease lists flanking left and rdecompose_segments
Open slide detailBeat · Market Size
07
The slide uses a 2x2-style matrix layout with an elliptical overlay representing clinical maturity stages (Preclinical to Marketed).compare_peers
Open slide detailBeat · Competition
08
The slide uses a standard pharmaceutical pipeline table format.plan_implementation
Open slide detailBeat · Roadmap
09
This is a section divider or cover slide for a specific product/therapy focus.front_matter
10
The slide highlights clinical efficacy and safety data from a Nature Medicine study (Mackensen et al., 2022) relevant to the company's CABA-201 construct.show_traction
11
The slide compares the CABA-201 construct components to established academic benchmarks and highlights clinical validation of the underlying binder technology.present_solution
12
The slide uses a numbered list format to structure the two primary pillars of their competitive advantage.summarize
13
transition
14
The slide uses a comparison table structure to differentiate between Mucosal PV and Mucocutaneous PV, followed by a list of clinical limitations of current stanframe_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
15
Includes Orphan Drug and Fast Track designation badges.plan_implementation
Open slide detailLoop · Cost Of Inaction
16
Includes detailed scientific citations and specific cohort dosing strategies.show_traction
Open slide detailLoop · Cost Of Inaction
17
Includes a molecular structure diagram of MuSK and a pie chart of MG patient segments.frame_problem
Open slide detailLoop · Cost Of Inaction
18
Includes specific dosing details and regulatory designations (Orphan Drug, Fast Track).plan_implementation
19
The slide uses a timeline-based process flow to illustrate capital allocation strategy.plan_implementation
20
transition
21
Includes headshots for the leadership team and lists for the board members.other
22
The slide uses a table format to present a roadmap of clinical milestones.plan_implementation
23
front_matter